Inositol (myo-Inositol)
Of 4,405 on-market inositol (myo-inositol) products in the January 2026 DSLD dump, the median declared dose is 30 mg, and 96.2% list unspecified/undisclosed form as the primary form.
Form share
Of 4,350 products with an identifiable primary form, here is the share held by each form of Inositol (myo-Inositol) on the market today.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
| Form | Quality tier | n | Share |
|---|---|---|---|
| unspecified/undisclosed form | Unrated | 4,183 | 96.2% |
| myo-Inositol | Unrated | 160 | 3.7% |
| D-chiro-Inositol | Unrated | 7 | 0.2% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mg), among 3,849 products with a disclosed amount.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
- 96.7% of products fall below the fairy-dust threshold (800 mg, 20% of the studied low dose).
- 12.3% of products don't disclose an amount because Inositol (myo-Inositol) is declared inside a proprietary blend.
Where does your dose rank?
Enter a per-serving dose (mg) to see exactly how it compares to the 3,849 on-market inositol (myo-inositol) products with a disclosed amount. The chart above groups doses into deciles; this looks up the exact percentile for one number.
By dosage form
By target group
Top brands
Search interest over time
How often people search for inositol (myo-inositol) on Google, US only, the last 5 years. This is public interest, not DSLD label data — a spike here doesn't necessarily line up with anything on this page, and Google's own index (100 = that term's peak popularity in the chosen window) is relative, not an absolute search-volume count.
Or see this search directly on trends.google.com.
Forms explained
Label discloses only "Inositol" with no salt or source form.
Most labels say only 'Inositol'; the clinical literature (PCOS, gestational diabetes, psychiatric trials) uses myo-inositol, which is therefore the default interpretation. No comparison of forms applies. No head-to-head human bioavailability or efficacy comparison of this form was located in PubMed searches.
Source: Santamaria A et al. 2016, PMID 26698911; Pundir J et al. 2018, PMID 28544572
A distinct stereoisomer, not a different delivery form of myo-inositol; it appears in PCOS products usually alongside myo-inositol. In an 18-volunteer crossover, adding 1,000mg D-chiro-inositol to 6,000mg myo-inositol reduced myo-inositol Cmax (1.29-fold) and AUC (19%).
Source: Garzon S et al. 2019, Expert Opin Drug Metab Toxicol 15(9):697-703, PMID 31382802
Reference values
- RDA (adult): not established — Endogenously synthesized from glucose and found in food; not an essential nutrient; no RDA/AI exists.
- Tolerable Upper Intake Level (adult): not established — Not established. A 1-month crossover trial gave up to 18g/day myo-inositol (Palatnik A et al. 2001, J Clin Psychopharmacol 21(3):335-9, PMID 11386498, n=20); typical supplement doses are far lower. This is not a formal UL.
- Studied clinical dose range: 4000–18000 mg
- Low end: Santamaria A et al. 2016, J Matern Fetal Neonatal Med 29(19):3234-7, PMID 26698911 -- open-label RCT, 220 overweight non-obese pregnant women, myo-inositol 2g + 200mcg folic acid twice daily (4g/day) vs folic acid alone from the first trimester; gestational diabetes incidence 11.6% vs 27.4% (OR 0.33). High end: Palatnik A et al. 2001, PMID 11386498 -- double-blind crossover, 20 panic-disorder patients, inositol up to 18g/day x1 month vs fluvoxamine up to 150mg/day; similar improvement on HAM-A and fewer panic attacks in month 1 (4.0 vs 2.4 fewer/week, p=0.049). PCOS evidence (e.g. Pundir J et al. 2018, BJOG 125(3):299-308, PMID 28544572: 10 RCTs, improved ovulation and cycle frequency with inositol) does not state doses in the abstract and is not used to set the range.
- Note: Matches the myo-inositol stereoisomer and unspecified 'Inositol'. D-chiro-inositol is a distinct stereoisomer with its own (PCOS-focused) use and is a form here, not folded into myo-inositol. Inositol hexanicotinate/niacinate is a niacin ester, phosphatidylinositol is a phospholipid and inositol hexaphosphate (IP6) is phytic acid; none is a myo-inositol supplement in the usual sense, so they are deliberately neither aliased nor modeled as forms (rows naming them stay unmatched; they do not fuzzy-match to this compound). Co-ingestion of D-chiro-inositol was reported to reduce myo-inositol absorption in an 18-volunteer study (Garzon S et al. 2019, PMID 31382802).